KROS · ISSUER CIK 1664710
Keros Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Keros Therapeutics, Inc. insiders reported $10K of open-market purchases and $101K of sales on SEC Form 4. The largest buyer was Bienaime Jean Jacques (Director), with $10K.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 4 sales were reported under a 10b5-1 plan.
$10KInsider buying
$101KInsider selling
−$91KNet open-market
Aug 20, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 202616:10 | Aug 18, 2026 | KROS | Corp. Controller & VP, Finance | S · Sell | $10.29 | −1,224 | 45,144 | -3% | −$13K | ||
| Aug 20, 202616:10 | Aug 18, 2026 | KROS | Chief Scientific Officer | S · Sell | $10.29 | −3,568 | 27,559 | -11% | −$37K | ||
| Aug 20, 202616:10 | Aug 18, 2026 | KROS | Chief Legal Officer | S · Sell | $10.29 | −4,485 | 35,770 | -11% | −$46K | ||
| Aug 20, 202616:10 | Aug 18, 2026 | KROS | Director | S · Sell10b5-1 | $10.30 | −551 | 12,114 | -4% | −$6K | ||
| Aug 19, 202616:10 | Aug 17, 2026 | KROS | Director | P · Buy10b5-1 | $10.27 | +1,000 | 19,592 | +5% | +$10K | -14.6% | +10.6% |